USP11 and neoplasm: Another DUB inhibitor, mitoxantrone, is FDA-approved to inhibit USP11 and has advanced to phase I/II clinical trials to target diseases, such as relapsed acute myeloid leukemia, neoplasms, advanced recurrent or metastatic breast cancer, multiple sclerosis, and neuromyelitis optica [228,229].